Drug-resistant genes at hepatitis B virus polymerase region during entecavir treatment.
- Author:
Xiao-feng GUO
1
;
Chao-xian ZHANG
;
Yan LIU
;
Fei WU
;
Xin LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; DNA, Viral; blood; genetics; DNA-Directed DNA Polymerase; genetics; Drug Resistance, Viral; genetics; Female; Guanine; analogs & derivatives; therapeutic use; Hepatitis B virus; enzymology; genetics; Hepatitis B, Chronic; drug therapy; virology; Humans; Male; Middle Aged; Mutation; Viral Proteins; genetics; Young Adult
- From: Acta Academiae Medicinae Sinicae 2013;35(4):444-446
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the drug-resistant genes at hepatitis B virus (HBV) polymerase region during entecavir (ETV) treatment.
METHODSSerum samples from chronic hepatitis B patients with virologic breakthrough during enticavir therapy were studied. The resistant mutation patterns in the polymerase gene of hepatitis B virus were analyzed using the polymerase chain reaction (PCR)-sequencing method.
RESULTSETV resistance was detected from 19 out of 29 ETV-refractory patients, among whom 16 (84.2%) had a history of lamivudine-refractory. The mutation patterns were diverse, while rtL180 + rtM204 + rtT184 (58.6%, 17/29) was most common in patients with ETV genotype resistance. Four of 7 patients (7/29, 24.1%) with genotype B were detected to have ETV genotype resistance, while 15 of 22 patients (22/29, 75.9%) with genotype C were detected to have ETV genotype resistance. The rate of ETV genotype resistance was 57.1% (4/7) and 68.2% (15/22) in patients with genotype B and genotype C,while no statistical difference was found(P = 0.665).
CONCLUSIONSETV genotype resistance is more common in patients who have been refractory to ETV and lamivudine sequential treatment. rtM204+rtL180+rtT184 mutation is common in genotype B and C ETV resistance patients.
